Maeda T, Eto M, Nishimura Y, Nomoto K, Kong Y Y, Nomoto K
Department of Immunology, Kyushu University, Fukuoka, Japan.
J Immunol. 1993 Feb 1;150(3):753-62.
The role of peripheral hemopoietic chimerism in the induction and maintenance of donor-specific tolerance was investigated by our tolerance-inducing method using cyclophosphamide (CP). As has been previously reported, CP injection at a dose of 200 mg/kg to C3H (Thy-1.2, Mls-1b) mice 2 days after priming with 10(8) viable AKR (Thy-1.1, Mls-1a) spleen cells (SC) resulted in both establishment of mixed chimerism and selective elimination of V beta 6+CD4+ T cells in the periphery. When, instead of viable SC, 1300 rad irradiated 10(8) AKR SC were used for priming to C3H mice, CP treatment 2 days after the priming also caused significant but, as compared with priming with nonirradiated viable cells, incomplete elimination of V beta 6+ T cells in the periphery. In these mice, no hemopoietic chimerism was found. In parallel with this incomplete elimination of peripheral V beta 6+ T cells, LN cells of these mice showed reduced but considerable response to AKR SC. However, once hemopoietic chimerism was introduced to these incompletely tolerant mice by an injection with donor-type viable [AKR x C3H]F1 SC 2 days after CP-treatment, LN cells from these newly established chimeras, irrespective of presence or absence of the thymus, became completely nonresponsive to AKR while preserving normal response to BALB/c (third party). This state of nonresponsiveness was accompanied by clonal elimination of the remaining V beta 6+ T cells in the periphery. These results indicate that peripheral chimerism promoted profound tolerance to donor-Mls Ag specifically. Furthermore, from experiments of skin grafting, we demonstrated that tolerance to minor histocompatibility Ag was also achieved in the presence of peripheral hemopoietic chimerism.
通过我们使用环磷酰胺(CP)的耐受诱导方法,研究了外周造血嵌合体在诱导和维持供体特异性耐受中的作用。如先前报道,在用10⁸个活的AKR(Thy-1.1,Mls-1a)脾细胞(SC)致敏后2天,给C3H(Thy-1.2,Mls-1b)小鼠注射剂量为200mg/kg的CP,导致外周混合嵌合体的建立以及Vβ6⁺CD4⁺T细胞的选择性清除。当用1300rad照射的10⁸个AKR SC代替活的SC用于致敏C3H小鼠时,致敏后2天的CP处理也导致外周Vβ6⁺T细胞的显著但与用未照射的活细胞致敏相比不完全的清除。在这些小鼠中,未发现造血嵌合体。与外周Vβ6⁺T细胞的这种不完全清除同时,这些小鼠的淋巴结细胞对AKR SC的反应降低但仍相当可观。然而,一旦在CP处理后2天通过注射供体型活的[AKR×C3H]F1 SC将造血嵌合体引入这些不完全耐受的小鼠中,来自这些新建立的嵌合体的淋巴结细胞,无论胸腺是否存在,对AKR完全无反应,同时保留对BALB/c(第三方)的正常反应。这种无反应状态伴随着外周剩余Vβ6⁺T细胞的克隆清除。这些结果表明外周嵌合体特异性地促进了对供体-Mls抗原的深度耐受。此外,通过皮肤移植实验,我们证明在外周造血嵌合体存在的情况下也实现了对次要组织相容性抗原的耐受。